Lineage Cell Therapeutics, Inc. (LCTX) is a Healthcare stock trading at $1.08 (as of 2026-08-21), with a market capitalization of $273.14M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Lineage Cell Therapeutics develops novel cell therapies for degenerative diseases, including OpRegen for dry age-related macular degeneration, OPC1 for acute spinal cord injuries, and VAC2 for cancer immunotherapy, and it makes money through collaboration and licensing-related revenue (currently reported as zero).
Because the company is clinical-stage with OpRegen, OPC1, and VAC2 in Phase I/IIa trials, near-term results in the form of patient enrollment and early clinical readouts matter most, while current collaboration and licensing revenue is reported as zero.
| Collab | $0.0B |
| RoyaltiesLicOther | $0.0B |
Business quality (Weak): Clear pipeline focus across multiple Phase I/IIa programs and observable trial activity metrics, but the near-term financial model shows zero reported revenue and a very large operating loss, making execution and trial outcomes critical.
| Price | $1.08 |
| Market Cap | $273.14M |
| Price / Book | 4.57 |
| Price / Sales | 20.88 |
| FCF Yield | -8.9% |
| Revenue (TTM) | $14.56M |
| Net Margin | -436.5% |
| Revenue Growth (YoY) | -61.3% |
| EPS Growth (YoY) | -107.7% |
| FCF Growth (YoY) | 32.4% |
| Altman Z-Score | -3.91 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | BROADWOOD CAPITAL INC ($78.31M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Brian Culley |
| Employees | 70 |
| Country | US |
| IPO Date | 1992-03-05 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.